Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)
Massimo Filippi, Jon Riolo, Jeffrey A. Cohen, Hans‐Peter Hartung, Xavier Montalbán, Sven G. Meuth, Léorah Freeman, Tanuja Chitnis, Cristina Granziera, Erik DeBoer, Chun-Yen Cheng, Jennifer Reardon, Chahin Pachaï, James K. Sheffield, Bruce Cree, Ludwig Kappos (2024). Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014). , 102(7_supplement_1), DOI: https://doi.org/10.1212/wnl.0000000000204935.
